Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

Completed · Phase 2

Conditions studied: Leukemia, Fungal Infection

In brief

The goal of this clinical research study is to learn the amount of posaconazole that is in the body at different time points when given to patients with leukemia. The safety of this drug will also be studied. Objectives: Primary: To study the plasma pharmacokinetics of posaconazole in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) undergoing induction chemotherapy or relapsed or refractory patients who will receive salvage chemotherapy. Secondary: To evaluate the safety of posaconazole given as prophylaxis.

Key facts

Study ID

NCT00936117

Run by

M.D. Anderson Cancer Center

People needed

25

Starts

2009-09-01

Expected to finish

2013-09-01

Last updated by the study team

2019-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients newly diagnosed with AML or high-risk MDS undergoing induction chemotherapy or refractory or relapsed patients with AML or high-risk MDS who will receive first or second salvage chemotherapy. (Salvage patients are defined as patients that achieved remission and relapsed or patients who were refractory to initial frontline chemotherapy)
• Age > 18 years and able to take oral intake.
• Patients must sign an informed consent.
• Patients agree to medically approved forms of contraception
• Patients on prior antifungal prophylaxis with voriconazole, itraconazole or fluconazole are eligible if they completed 3 days wash-out period if on voriconazole, or 14 days wash-out period if on itraconazole or 7 days wash-out period if on fluconazole

You may not qualify if…

• Patients with history of anaphylaxis attributed to azole compounds
• Patients with clinical or other evidence that indicates that they have proven or probable invasive fungal infection prior to enrollment (EORTC criteria)
• Patients with baseline total bilirubin levels > 3 times the upper normal limits (i.e. > 3.0 mg/dl); or baseline SGPT > 5 times upper limit normal.
• Patients receiving any medication that is contraindicated with the use of posaconazole
• Patients with baseline creatinine levels NCI grade 3 or above (> 3.0 - 6.0 X ULN)
• Patients with baseline QTc prolongation NCI grade 1 or above (QTc > 0.45 - 0.47 seconds).

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.